{"id":"NCT00971425","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","officialTitle":"Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-08","primaryCompletion":"2009-11-16","completion":"2010-10-08","firstPosted":"2009-09-03","resultsPosted":"2011-03-04","lastUpdate":"2018-08-17"},"enrollment":145,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Pandemrix (GSK investigational influenza GSK2340272A vaccine)","otherNames":[]},{"type":"BIOLOGICAL","name":"Fluarixâ„¢","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo-Pandemrix-Fluarix Group","type":"EXPERIMENTAL"},{"label":"Fluarix-Pandemrix-Placebo Group","type":"EXPERIMENTAL"}],"summary":"The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Antibodies Against Pandemrix Vaccine Strain","timeFrame":"At Day 42","effectByArm":[{"arm":"Placebo-Pandemrix-Fluarix Group","deltaMin":309.8,"sd":null},{"arm":"Fluarix-Pandemrix-Placebo Group","deltaMin":227.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"61 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":6,"countries":["Germany"]},"refs":{"pmids":["22885014"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":72},"commonTop":["Pain","Muscle aches","Headache","Fatigue","Joint pain at other location"]}}